NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has begun negotiations with the National Institute of Allergy and Infectious Diseases (NIAID) to obtain supplemental funding for its existing $16.5 million contract for the development of its smallpox antiviral drug candidate, ST-246.
